XT
RVNC

XTX Topco’s Revance Therapeutics, Inc. RVNC Stock Holding History

XTX Topco’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,381
Closed -$142K – 3083
2024
Q3 		$142K Sell
27,381
-42,545
-61% -$211K 0.01% 1543
2024
Q2 		$180K Buy
69,926
+15,267
+28% +$52.1K 0.02% 1277
2024
Q1 		$269K Buy
+54,659
New +$324K 0.04% 943
2023
Q4 		– Sell
-19,908
Closed -$228K – 2258
2023
Q3 		$228K Buy
19,908
+2,382
+14% +$45.8K 0.04% 935
2023
Q2 		$444K Buy
17,526
+7,311
+72% +$228K 0.08% 443
2023
Q1 		$329K Sell
10,215
-24
-0.2% -$748 0.07% 582
2022
Q4 		$189K Buy
+10,239
New +$234K 0.04% 867
2021
Q3 		– Sell
-7,323
Closed -$217K – 1129
2021
Q2 		$217K Buy
+7,323
New +$211K 0.07% 527

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

XTX Topco's RVNC Position: Q4 2024 in Review

XTX Topco sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 27,381 shares — an estimated $142K sold.

XTX Topco first reported a position in RVNC in Q2 2021 and held it in 8 quarters. The position peaked at $444K in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • XTX Topco reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • XTX Topco sold 27,381 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $142K.
  • XTX Topco first reported a position in Revance Therapeutics, Inc. in Q2 2021 and held it in 8 quarters.
  • XTX Topco's Revance Therapeutics, Inc. position peaked at $444K in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on XTX Topco's 13F filing for Q4 2024, filed 13 Feb 2025.